drugset / Trial / NCT05650580
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A phase 1 dose escalation and expanded cohort study of TR115 in the treatment of adult patients with relapsed/refractory non-hodgkin's lymphoma or advanced solid tumors.
Timeline
- Start
- 2023-04-23
- Primary completion
- 2025-07-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TR115 | Unknown | 100 mg | Oral |
| Subject | TR115 | Unknown | 200 mg | Oral |
| Subject | TR115 | Unknown | 400 mg | Oral |
| Subject | TR115 | Unknown | 800 mg | Oral |
| Subject | TR115 | Unknown | 1200 mg | Oral |
| Subject | TR115 | Unknown | 1600 mg | Oral |